Literature DB >> 10969081

Restoration of correct splicing of thalassemic beta-globin pre-mRNA by modified U1 snRNAs.

L Gorman1, D R Mercatante, R Kole.   

Abstract

The T-->G mutation at nucleotide 705 in the second intron of the beta-globin gene creates an aberrant 5' splice site and activates a 3' cryptic splice site upstream from the mutation. As a result, the IVS2-705 pre-mRNA is spliced via the aberrant splice sites leading to a deficiency of beta-globin mRNA and protein and to the genetic blood disorder thalassemia. We have shown previously that in cell culture models of thalassemia, aberrant splicing of beta-thalassemic IVS2-705 pre-mRNA was permanently corrected by a modified murine U7 snRNA that incorporated sequences antisense to the splice sites activated by the mutation. To explore the possibility of using other snRNAs as vectors for antisense sequences, U1 snRNA was modified in a similar manner. Replacement of the U1 9-nucleotide 5' splice site recognition sequence with nucleotides complementary to the aberrant 5' splice site failed to correct splicing of IVS2-705 pre-mRNA. In contrast, U1 snRNA targeted to the cryptic 3' splice site was effective. A hybrid with a modified U7 snRNA gene under the control of the U1 promoter and terminator sequences resulted in the highest levels of correction (up to 70%) in transiently and stably transfected target cells.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10969081     DOI: 10.1074/jbc.M006259200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  mRNA transcript diversity creates new opportunities for pharmacological intervention.

Authors:  Elizabeth S Barrie; Ryan M Smith; Jonathan C Sanford; Wolfgang Sadee
Journal:  Mol Pharmacol       Date:  2012-02-07       Impact factor: 4.436

2.  An apparent pseudo-exon acts both as an alternative exon that leads to nonsense-mediated decay and as a zero-length exon.

Authors:  Sushma-Nagaraja Grellscheid; Christopher W J Smith
Journal:  Mol Cell Biol       Date:  2006-03       Impact factor: 4.272

3.  A prospective study in the rational design of efficient antisense oligonucleotides for exon skipping in the DMD gene.

Authors:  Zacharias Aloysius Dwi Pramono; Keng Boon Wee; Jian Li Wang; Yi Jun Chen; Qian Bin Xiong; Poh San Lai; Woon Chee Yee
Journal:  Hum Gene Ther       Date:  2012-07-13       Impact factor: 5.695

4.  Dynamics of co-transcriptional pre-mRNA folding influences the induction of dystrophin exon skipping by antisense oligonucleotides.

Authors:  Keng Boon Wee; Zacharias Aloysius Dwi Pramono; Jian Li Wang; Karl F MacDorman; Poh San Lai; Woon Chee Yee
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

5.  Enhancement of β-Globin Gene Expression in Thalassemic IVS2-654 Induced Pluripotent Stem Cell-Derived Erythroid Cells by Modified U7 snRNA.

Authors:  Phetcharat Phanthong; Suparerk Borwornpinyo; Narisorn Kitiyanant; Natee Jearawiriyapaisarn; Lalana Nuntakarn; Jirawat Saetan; Tiwaporn Nualkaew; Khanit Sa-Ngiamsuntorn; Usanarat Anurathapan; Andras Dinnyes; Yindee Kitiyanant; Suradej Hongeng
Journal:  Stem Cells Transl Med       Date:  2017-02-18       Impact factor: 6.940

Review 6.  Viral Vector-Mediated Antisense Therapy for Genetic Diseases.

Authors:  Marine Imbert; Gabriella Dias-Florencio; Aurélie Goyenvalle
Journal:  Genes (Basel)       Date:  2017-01-26       Impact factor: 4.096

7.  Chimeric snRNA molecules carrying antisense sequences against the splice junctions of exon 51 of the dystrophin pre-mRNA induce exon skipping and restoration of a dystrophin synthesis in Delta 48-50 DMD cells.

Authors:  Fernanda Gabriella De Angelis; Olga Sthandier; Barbara Berarducci; Silvia Toso; Giuliana Galluzzi; Enzo Ricci; Giulio Cossu; Irene Bozzoni
Journal:  Proc Natl Acad Sci U S A       Date:  2002-06-20       Impact factor: 11.205

8.  The Cellular Processing Capacity Limits the Amounts of Chimeric U7 snRNA Available for Antisense Delivery.

Authors:  Agathe Eckenfelder; Julie Tordo; Arran Babbs; Kay E Davies; Aurélie Goyenvalle; Olivier Danos
Journal:  Mol Ther Nucleic Acids       Date:  2012-06-26       Impact factor: 10.183

9.  An Exon-Specific U1snRNA Induces a Robust Factor IX Activity in Mice Expressing Multiple Human FIX Splicing Mutants.

Authors:  Dario Balestra; Daniela Scalet; Franco Pagani; Malgorzata Ewa Rogalska; Rosella Mari; Francesco Bernardi; Mirko Pinotti
Journal:  Mol Ther Nucleic Acids       Date:  2016-10-04       Impact factor: 10.183

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.